Publications by authors named "XiNan Sheng"

Claim this Profile
T
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.
Xinan Sheng, Gang Huang, Meiyu Fang, Ke Li, Di Wu

JAMA Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MARCO+ Tumor-Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma.
Jiayuan Chen, Jiazhi Mo, Jinchang Wei, Mengnan Qu, Jie Dai, Xinan Sheng

Adv Sci (Weinh)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.
Xinan Sheng, Gongqian Zeng, Cuijian Zhang, Qingyun Zhang, Jiasheng Bian

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer.
Yelin Mulati, Qi Shen, Yuke Chen, Yuxuan Tian, Kaifeng Yao, Xinan Sheng

Prostate Cancer Prostatic Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy.
Mengnan Qu, Jinchang Wei, Jiazhi Mo, Jiayuan Chen, Xiaowen Wu, Xinan Sheng

Urol Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sintilimab Plus Axitinib for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
Xingming Zhang, Haoyang Liu, Jiayu Liang, Junjie Zhao, Yongquan Wang, Xinan Sheng

JAMA Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial.
Aiping Zhou, Pengfei Shen, Juan Li, Wang Qu, Zengjun Wang, Xinan Sheng

Lancet Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in antibody-drug conjugates for urothelial carcinoma treatment.
Jinchang Wei, Bixia Tang, Xieqiao Yan, Juan Li, Li Zhou, Xinan Sheng

Cancer Biol Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study.
Xieqiao Yan, Juan Li, Huayan Xu, Yiqiang Liu, Li Zhou, Xinan Sheng

Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma.
Jiaran Zhang, Huichun Tian, Lili Mao, Caili Li, Xiaoting Wei, Xinan Sheng

Cancer Manag Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets.
Xingming Zhang, Junjie Zhao, Xiaoxue Yin, Jiayu Liang, Yongquan Wang, Xinan Sheng, Mingsheng Liu

Nat Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Characteristics and Impact on Prognosis of Melanoma Accompanied by Multiple Primary Malignancies: A Retrospective Analysis.
Huichun Tian, Jiaran Zhang, Lili Mao, Caili Li, Xiaoting Wei, Xinan Sheng

Cancer Invest· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic characterization reveals distinct mutational landscape of acral melanoma in East Asian.
Fenghao Zhang, Xiaowen Wu, Tao Jiao, Haizhen Du, Qian Guo, Xinan Sheng

J Genet Genomics· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 Therapy.
Linzi Sun, Xiaoting Wei, Qian Zhao, Lili Mao, Xue Bai, Xinan Sheng

J Extracell Vesicles· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy.
Siming Li, Jinchang Wei, Huayan Xu, Xiaowen Wu, Juan Li, Xinan Sheng

World J Urol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predominance of hyperprogression in mucosal melanoma during anti-PD-1 monotherapy treatment.
Li Zhou, Min Cao, Haibin Zhu, Zhihong Chi, Chuanliang Cui, Xinan Sheng

Oncologist· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma.
Bixia Tang, Jun Xiao, Zhihong Chi, Rong Duan, Chuanliang Cui, Xinan Sheng

Oncologist· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights.
Xuan Wang, Hui Tian, Zhihong Chi, Lu Si, Xinan Sheng

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular subtyping in urothelial carcinoma treatment.
Xiaowen Wu, Xinan Sheng

Cancer Cell· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China.
Siming Li, Yanxia Shi, Haiying Dong, Hongqian Guo, Yu Xie, Xinan Sheng

Cancer Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial.
Jiayong Liu, Xuan Wang, Zhongwu Li, Shunyu Gao, Lili Mao, Xinan Sheng

Signal Transduct Target Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On the shoulder of ADC: The development of I-IMMU-132, an iodine-124-labelled Trop-2-targeting molecular probe for micro-PET imaging.
Ziqing Zeng, Yong Zheng, Xieqiao Yan, Jinping Tao, Liqiang Li, Xi'nan Sheng

Biomed Pharmacother· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A narrative review of advances in the management of urothelial cancer: Diagnostics and treatments.
Shaoxu Wu, Shengwei Xiong, Juan Li, Guibin Hong, Ye Xie, Xinan Sheng

Bladder (San Franc)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Junru Chen, Xu Hu, Junjie Zhao, Xiaoxue Yin, Linmao Zheng, Xinan Sheng

Clin Cancer Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural history of bone-only metastasis in renal cell carcinoma.
Bixia Tang, Rong Duan, Zenan Fan, Xieqiao Yan, Siming Li, Xinan Sheng

Urol Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis